RNA Disruption Assay™ Test Can Determine Degree of Ribosomal RNA Disruption During Chemotherapy Rna Diagnostics Inc. is a Toronto-based early-stage molecular diagnostics company that is developing medical diagnostic tools to assist in the management of cancer. The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. The RDA™ test can determine whether chemotherapy is working effectively in an individual patient early in treatment, thereby enabling more effective clinical decision-making. RDA™ utilizes a needle biopsy taken during cancer treatment to determine the degree of ribosomal RNA (rRNA) disruption, which is a reliable biomarker of impending cell death. Higher rRNA disruption indicates higher effectiveness of a patient’s cancer treatment. Rna Diagnostics is conducting a pivotal clinical trial in primary breast cancer called BREVITY (Breast Cancer Response EValuation for Individualized TherapY), involving 700+ primary breast cancer patients in approximately 40 medical centers across North America and Europe. Rna Diagnostics also has collaborations in progress for rectal, head and neck and metastatic breast cancers. The RNA Disruption Assay test is currently available for clinical trial use from a state-of-the-art laboratory in Sudbury, Ontario, Canada. Rna Diagnostics was founded in 2010 and is backed by both public and private investors, including the Ontario Centres of Excellence, Health Technology Exchange, Ontario Genomics Institute, Northern Ontario Heritage Fund Corporation, Temple Rock Holdings, Northern Cancer Foundation, and Crux Capital, among others. In upcoming news, Rna Diagnostics is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City. Learn more and register to attend the conference at www.nyconcologyconference.com.